View news from other Pharmaceutical sectors:
91-105 of 385 results
OWH signs patent agreement with Eisai for pro-drug technology
OneWorld Health (OWH) has entered into a nonexclusive patent agreement with Eisai for a water-soluble pro-drug technology patent.
Inward Investment > News
Inward Investment > News
Bausch + Lomb to purchase ISTA
Bausch + Lomb has signed a definitive agreement to acquire ISTA Pharmaceuticals for $9.10 per share in cash, or a total of approximately $500m.
Inward Investment > News
Inward Investment > News
Sanofi to purchase Pluromed
Sanofi has entered into an agreement to acquire Pluromed, a medical device company based in Woburn, Massachusetts, US.
Inward Investment > News
Inward Investment > News
CareFusion signs deal to acquire Phacts
CareFusion has signed an agreement to acquire Phacts, a Seattle-based technology and consulting company that helps hospital pharmacies better manage inventory, reduce pharmaceutical costs and streamline operations.
Inward Investment > News
Inward Investment > News
Islet Sciences to take over DiaKine Therapeutics
Islet Sciences has entered into a share exchange agreement to acquire DiaKine Therapeutics (DTI), a development stage company commercializing novel immune modulators for the treatment of diabetes and related complications.
Inward Investment > News
Inward Investment > News
Dompé to acquire Italian ophthalmology company
Italy's biopharmaceutical company, Dompé has signed a definitive agreement to acquire remaining 51% stake in Anabasis, a privately held Italian research and development biopharmaceutical company.
Inward Investment > News
Inward Investment > News
Catalent takes over Aptuit clinical trial supplies business
Catalent Pharma Solutions has completed the acquisition of the clinical trial supplies business of Aptuit.
Inward Investment > News
Inward Investment > News
Valeant to purchase Eyetech
Valeant Pharmaceuticals has entered into an agreement to acquire Eyetech, a privately-owned ophthalmic biotechnology company.
Inward Investment > News
Inward Investment > News
Bristol-Myers Squibb takes over Inhibitex
Bristol-Myers Squibb Company has completed its acquisition of Inhibitex, a drug development company, at a purchase price of $26 per share.
Inward Investment > News
Inward Investment > News
Navidea opens business, commercial development office in Massachusetts
US-based specialty pharmaceutical company, Navidea Biopharmaceuticals has opened a business and commercial development office in Andover, Massachusetts, US.
Inward Investment > News
Inward Investment > News
Alexion takes over Enobia
Alexion Pharmaceuticals has completed its acquisition of 100% of the capital stock of Enobia Pharma, a private biopharmaceutical company.
Inward Investment > News
Inward Investment > News
Medicago to invest in pilot production facility
Medicago has announced plans to invest around $4m to increase the capacity of the pilot production facility located in Quebec City, the capital of the Canadian province of Quebec.
Inward Investment > News
Inward Investment > News
Sigma-Aldrich takes over BioReliance for $350m
Sigma-Aldrich, a life science and high technology company, has completed its purchase of BioReliance from Avista Capital Partners for $350m in cash.
Inward Investment > News
Inward Investment > News
Mission Pharmacal launches new subsidiary
Mission Pharmacal Company has launched a new Doylestown, Pennsylvania, based subsidiary, Alamo Pharma Services.
Inward Investment > News
Inward Investment > News
Watson Pharmaceuticals buys Ascent Pharmahealth
Watson Pharmaceuticals has purchased Ascent Pharmahealth, the Australia and Southeast Asia generic pharmaceutical business of Strides Arcolab.
Inward Investment > News
Inward Investment > News
Suppliers Directory
Boehringer Ingelheim - Drug Substance and Drug Product Services
Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates in 50 countries and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed for 125 years to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
Inward Investment > Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
In Inward Investment
Inward Investment Intelligence
ProtoDynamic Therapy: A Novel Therapeutic Concept for Inflammation and Cancer
Published by BioCis Pharma
Inward Investment > White Papers
Buy the latest industry research online today!
African Pharmaceutical Directory 2013
API research into pharmaceutical companies and corporations Buy online from $200
API research into pharmaceutical companies and corporations Buy online from $200
